Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12304393 | 0.93 | KCNH2 (0.73) | KCNH2CYP2C19CYP3A4CYP2C9P2RY1 | |
| SCHEMBL12303356 | 0.91 | KCNH2 (0.67) | KCNH2CYP2C19CYP3A4CYP2C9P2RY1 | |
| SCHEMBL12303358 | 0.88 | KCNH2 (0.64) | KCNH2CYP2C19CYP3A4CYP2C9P2RY1 | |
| SCHEMBL12818227 | 0.87 | KCNH2 (0.63) | KCNH2CYP2C19CYP3A4CYP2C9P2RY1 | |
| SCHEMBL12304384 | 0.83 | KCNH2 (0.79) | KCNH2CYP2C19CYP3A4CYP2C9P2RY1 | |
| SCHEMBL12303712 | 0.76 | KCNH2 (0.74) | KCNH2CYP2C19CYP3A4CYP2C9P2RY1 | |
| SCHEMBL12303380 | 0.74 | CYP2C19 (0.81) | KCNH2CYP2C19CYP3A4CYP2C9NR3C1 | |
| SCHEMBL12303781 | 0.72 | CYP2C19 (0.66) | KCNH2CYP2C19CYP3A4CYP2C9NR3C1 | |
| SCHEMBL12303697 | 0.72 | KCNH2 (0.67) | KCNH2CYP2C19CYP3A4CYP2C9P2RY1 | |
| SCHEMBL12303381 | 0.71 | CYP2C19 (0.67) | KCNH2CYP2C19CYP3A4CYP2C9NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | KCNH2 3631/4885CYP2C19 712/4885CYP3A4 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.